OPPI

Daily News Monitor

July 28, 2016

1. **Incoming Lilly CEO says deal making will be a focus – Reuters**

   Eli Lilly & Co will likely step up the pace of making deals with other drugmakers while aggressively developing new drugs on its own, the company's newly appointed chief executive said on Wednesday. Company veteran David Ricks will become CEO on Jan. 1, after John Lechleiter, 62, retires by year-end, the Indianapolis-based drugmaker said.

2. **Scientists find potential new antibiotic, right under their noses – Reuters**

   Scientists in Germany have discovered a bacteria hiding out in peoples' noses that produces an antibiotic compound that can kill several dangerous pathogens, including the superbug MRSA. The early-stage finding, reported in the journal Nature on Wednesday, could one day lead to a whole new class of antibiotic medicines being developed to fight drug-resistant bacterial infections, the researchers said.

   As well as being a focal point for many viral infections, the nasal cavity is also a rich ecosystem of 50 or so different species of bacteria, lead researcher Andreas Peschel of the University of Tuebingen told reporters in a telephone briefing.

3. **BRIEF-Almirall signs license deal with Sun Pharma for psoriasis treatment – Reuters**

   Almirall SA :

   * Says enters into a license agreement with Sun Pharma Industries for tildrakizumab in Europe for psoriasis

   * Says to pay Sun Pharma an initial upfront payment of $50 million

   * Says Sun Pharma will be eligible to get milestone payments, sales milestone payments and royalties on net sales.

4. **Govt working on regulating web pharmacy: Sitharaman – The Times of India**

   The Health Ministry and Central Drugs Standard Control Organisation (CDSCO) are working to see how the online sale of medicines can be regulated, Rajya Sabha was informed today. The availability of essential medicines are also regularly reviewed by the Ministry and the National Pharmaceutical Pricing Authority and steps taken to keep their prices at affordable levels. "These periodic reviews are done with all seriousness. These reviews are being done aiming at

ensuring that such drugs are made available and at affordable rates," Commerce Minister Nirmala Sitharaman said during Question Hour.

5. **NCDs burden in Punjab: experts seek investment in healthcare – The Times of India**
With a survey by a leading health sector research organisation indicating a "growth in Non-Communicable Diseases (NCDs) related mortality" in Punjab, experts on Wednesday sought effective surveillance and greater investment in health care. "According to a state-wide survey by PGIMER along with four medical colleges in 2014-2015, Punjab has been witnessing a disturbing growth in NCDs related mortality," Partnership to Fight Chronic Disease (PFCD), a global organisation committed to raising awareness about NCDs, noted here on Wednesday.

6. **Glenmark gets USFDA nod for potassium chloride tablets – Moneycontrol.com**
Glenmark Pharmaceuticals has received final approval from the US health regulator for Potassium Chloride Extended Release Tablets, used in treating low levels of potassium in blood. "Glenmark Pharmaceuticals Inc, USA has been granted final approval by the US Food and Drug Administration (USFDA) for Potassium Chloride Extended Release Tablets USP, 10mEq (750 mg) and 20mEq (1500mg)," it said in a BSE filing. The tablet is a generic version of K-Dur extended release tablets of Merck Sharp and Dohme Corp.

7. **Lupin gets USFDA tentative nod for generic Lexiva tablets – Moneycontrol.com**
Drug firm Lupin has received tentative approval from the US health regulator to market generic Lexiva tablets used for treatment of HIV infection in the American market. The company's "US subsidiary Lupin Pharmaceuticals Inc has received tentative approval from the United States Food and Drug Administration (USFDA) to market a generic equivalent of ViiV Healthcare's Lexiva tablets, 700 mg (fosamprenavir calcium tablets, 700 mg)," Lupin said in a filing to BSE.

8. **Sun Pharma Recalls 16,000 Bottles Of Antidepressant Tablets In US – NDTV.com**
Drug major Sun Pharmaceutical Industries is recalling over 16,000 bottles of anti-depressant tablets from the US market due to failed dissolution specifications. The BuPROPion hydrochloride extended release tablets were manufactured at the company's Halol facility. Sun Pharmaceutical Industries Inc, the company's US subsidiary, is recalling 16,085 bottles of BuPROPion hydrochloride extended release tablets in the strength of 150 mg in a ongoing voluntary nationwide recall, the latest enforcement report of the US Food and Drug Administration (FDA) said.

9. **Pharma cos engaged in R&D need to understand changes happening in the sector: Dr Shailesh Ayyangar – Pharmabiz.com**
Considering the changes happening in health and pharma sectors world over, the pharmaceutical companies engaged in research and development (R&D) activities in India must figure out and comprehend the transformation and adopt measures to replicate it. In the western world, the R&D activities in pharmaceutical area are going through turmoil due to regulatory hurdles and the political developments there. Similar challenges are occurring in the field of innovation in India also, according to Dr Shailesh Ayyangar, president of the Organisation of Pharmaceutical Producers of India (OPPI), and the managing director of Sanofi India Limited. As far as Indian pharma sector is concerned, the major pharma companies in the country are concentrated on targeted therapies. Understanding of diseases helps for major changes in research. India has a number of manufacturing companies to undertake research activities for targeted therapies. The situation needs the support of the government in large scale.

10. **Govt permitted 74% FDI in Pharma sector – Indiainfoline.com**
FDI in Brownfield pharma sector has been permitted upto 74% under automatic route; and FDI beyond 74% and upto 100% is allowed under Government approval route. The move to permit 74% FDI under automatic route in Brownfield pharmaceutical sector is aimed at attracting

required capital, international best practices and latest technologies in the sector. Further, 100% FDI under automatic route is permitted for Greenfield pharma sector. The Government while reviewing FDI policy on pharma sector has put in place necessary safeguards by providing that non-compete clause would not be permitted.